Global Health Agencies and Vaccine-Preventable Deaths Debate
Full Debate: Read Full DebateCatherine West
Main Page: Catherine West (Labour - Hornsey and Friern Barnet)Department Debates - View all Catherine West's debates with the Foreign, Commonwealth & Development Office
(3 months, 2 weeks ago)
Westminster HallWestminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
It is a pleasure to serve under your chairmanship today, Sir Gary. I thank my hon. Friend the Member for Ealing, Southall (Mr Sharma) for his commitment over the years to public health and international development. He is known for his work on tuberculosis and for chairing the all-party parliamentary group on global tuberculosis, but he has also shone on AIDS and malaria, and I thank him for that. I should refer to my entry in the Register of Members’ Financial Interests in relation to a visit to Malawi last July with the all-party parliamentary group on malaria and neglected tropical diseases, which I chair. As part of chairing the group, I also have an unpaid role as a trustee at the Liverpool School of Tropical Medicine.
This debate is timely: as I was coming to Westminster Hall, I noticed on the news that five babies in the UK have died of whooping cough. That just shows that if we let our vaccination rates drop domestically, it can have an impact. A lesson that we learn through our own mortality is that we must always keep up with public health measures. This debate is also of global importance, and we all agree that ending preventable deaths is an international development priority and a core pillar of our overseas development assistance strategy.
Immunisation is one of the most successful and cost-effective global health interventions in history, and I am particularly proud of the role that the UK, and the last Labour Government specifically, had in inventing the Department for International Development and leaving a legacy where the Global Fund, Gavi, the Vaccine Alliance and Unitaid were able to group together to fight AIDS, tuberculosis and malaria. Sadly, in the last couple of years the numbers have plateaued, particularly in relation to malaria. They have not continued to fall as we would wish, and we must redouble our efforts to address that. As hon. Members have said, this debate follows World Immunisation Week. I should also note that the all-party parliamentary group on malaria and neglected tropical diseases was in Dundee and saw the drug discovery unit, and I am pleased that the hon. Member for Dundee West (Chris Law) mentioned its important work on developing the vaccine.
As we know, one of the key principles of the sustainable development goals is that we leave no one behind, and the hon. Member for Dundee West outlined the lessons that we learned through the covid-19 pandemic and how we must redouble our efforts to address those. Last July, on a visit to Mitundu Community Hospital in Malawi, I was able to see at first hand the critical work of the expanded programme on immunisation. The hospital is an hour south of the capital Lilongwe, and it is where, in 2019, a little girl named Lusitana became the first child in the world to receive a dose of the groundbreaking and British-backed RTS,S malaria vaccine. During the visit, I also met five-year-old Evison Saimon, the second child to receive the vaccine in all its doses. Saimon and his mother talked about how delighted they were not to have malaria in their household. We can read all the things we like, but it really comes home to us when we actually go and meet families abroad and see this important work being done.
We also heard from representatives of Malawi’s expanded programme on immunisation and the national malaria control programme about how the pilot programme is being rolled out, with safety concerns managed and household surveys showing the positive impact on individual families and communities. Since the introduction of the vaccine, Malawi has seen a consistent reduction in cases and deaths in the age group eligible to receive the vaccine. Across the three pilot countries—Ghana, Kenya and Malawi—more than 4.5 million doses have been administered through the implementing countries’ routine immunisation programmes, reaching nearly 1.7 million children. The World Health Organisation estimates that RTS,S could save the lives of an additional 40,000 to 80,000 African children each year once implemented at scale. It is especially important to note that the pilot was financed through an unprecedented collaboration between three global health funding bodies—Gavi, the Global Fund and Unitaid, with GSK donating up to 10 million doses. We have so many good examples of GSK’s UK involvement, which we can all be proud of.
At this critical juncture in the fight against malaria, we really must not allow global progress to continue to stall. We must support the groundbreaking malaria vaccines and see how other countries, such as the 28 countries across Africa that are due to roll out a vaccine in the next few years, go with the roll-out of the programme. Vaccines have a limited impact if they do not reach the communities that need them most and are not joined up with other strategies, such as insecticide bed nets—I know that colleagues here have seen those—and occasional spraying, which we also saw when we were in Malawi. We also know that health data management systems are crucial to understanding the impact of those important measures.
Not only does immunisation save lives, but it has a profound knock-on effect for families, communities and countries. The economy is helped enormously in many parts of the world by such important, life-saving initiatives. As part of Gavi’s mission to save lives and protect people’s health by increasing the equitable and sustainable use of vaccines, it has helped to vaccinate more than 1 billion children in 78 lower-income countries.
Other hon. Members have mentioned the opportunity for more manufacturing in country. I was pleased that FCDO representatives and other partners recently joined us for a roundtable in the House to talk about the opportunity to work with the Serum Institute, which was so crucial during covid-19. That would be a triangular partnership between India, the UK and many African countries. The hon. Member for Dundee West has seen that in action in South Africa, and I am sure that it can be rolled out across other African countries too.
I would be grateful if the Minister could update us on the Government’s intention to continue to support these vital global agencies in working to end vaccine-preventable deaths with strong pledges at the upcoming replenishments of Gavi and the Global Fund. Will he also update the House on the steps that the Government are taking to help to build and support research and development, as well as manufacturing, in particular to build capacity in vaccine manufacturing?
On the British science side, which is so important, what is the Minister doing to support the higher education sector, particularly where we have important collaborations? There have been setbacks due to Brexit and bumps along the road. What is he doing to promote and support our excellence in research, particularly the deep pockets of research in our universities? They sometimes report feeling a bit unsupported, and I know that the Minister will wish to put on record his support for international students being welcomed in the UK and for the rebuilding of collaborations across Europe, as well as for work with US partners and in country in Africa. I look forward to hearing his thoughts.